LunG and Melanoma canceR pAtients coVId19 Disease (GRAVID)

Spanish Lung Cancer Group886 enrolled

Overview

This is a multi-centre study on lung cancer patients which experienced COVID-19. Information on clinical features, clinical course, management and outcomes will be collected for both, thoracic cancers and COVID-19 infection. Firstly, investigators will be registered in an online secure registry. After that, a protocol will be developed in order to collect clinical data for the research. It will also include I on the care organization or the perception of the patient and their family members. The final stage will consist on retrospective data collection from patients. So, it is a retrospective study data collection, preceded by prospective data registry.

Study Type

OBSERVATIONAL

Enrollment

886

Conditions

Covid-19 Lung Cancer

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patients diagnosed with lung cancer * Patients who have contracted COVID-19 infection Exclusion Criteria: * Patients diagnosed with lung cancer but no confirmation of COVID-19 infection.

Locations (75)

Complejo Hospitalario Universitario de Ferrol

Ferrol, A Coruña, Spain

H. Clínica Benidorm

Benidorm, Alicante, Spain

Hospital de Elche

Elche, Alicante, Spain

Hospital General Universitario de Elda

Elda, Alicante, Spain

Hospital de Torrevieja

Torrevieja, Alicante, Spain

Hospital Universitari Germans Trias i Pujol

Badalona, Barcelona, Spain

Cetir Centre Mèdic

Esplugues de Llobregat, Barcelona, Spain

Hospital General de Granollers

Granollers, Barcelona, Spain

Hospital Instituto Onkologikoa

Donostia / San Sebastian, Basque Country, Spain

Hospital Universitario de Galdakao

Galdakao, Bizkaia, Spain

...and 65 more locations

Outcomes

Primary Outcomes

Clinical data of lung cancer patients with COVID-19 diagnoses

Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as clinical data.

Time frame: From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 years

Diagnosis data

Describe characteristics and evolution of Spanish patients preferably with lung cancer who contract COVID 19 infection with identification and study of factors of interest, as well as data about diagnosis

Time frame: From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 years

Treatments received

Time frame: From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 years

Prognostic factors

Time frame: From the diagnosis of the COVID until the patient is cured or dies, whichever comes first, assessed up to 5 years